Stevanato Group S.p.A. (STVN)
| Market Cap | 4.98B -16.7% |
| Revenue (ttm) | 1.39B +7.0% |
| Net Income | 162.96M +12.6% |
| EPS | 0.59 +11.1% |
| Shares Out | 273.00M |
| PE Ratio | 31.00 |
| Forward PE | 24.77 |
| Dividend | $0.06 (0.35%) |
| Ex-Dividend Date | Jun 5, 2025 |
| Volume | 655,732 |
| Open | 18.48 |
| Previous Close | 18.03 |
| Day's Range | 17.95 - 18.76 |
| 52-Week Range | 12.89 - 28.00 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | 25.67 (+40.81%) |
| Earnings Date | May 7, 2026 |
About STVN
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injector... [Read more]
Financial Performance
In 2025, Stevanato Group's revenue was 1.19 billion, an increase of 7.45% compared to the previous year's 1.10 billion. Earnings were 139.84 million, an increase of 18.73%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for STVN stock is "Buy." The 12-month stock price target is $25.67, which is an increase of 40.81% from the latest price.
News
Stevanato Group Earnings Call Transcript: Q1 2026
Q1 2026 saw 10% revenue growth at constant currency, driven by strong BDS segment performance and high-value solutions, especially GLP-1s. Engineering margins improved despite lower revenue. Guidance for 2026 is maintained, with robust demand for syringes and cartridges and ongoing capacity expansions.
Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group to Participate in Three Upcoming Investor Conferences
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group management to meet with KeyBanc
Meeting to be held in New York on March 26 hosted by KeyBanc.
Stevanato Group Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Strong growth in high-value solutions and biologics drove margin expansion and record revenues in 2025, with further gains expected in 2026. Major capacity investments in sterile cartridges and drug delivery systems support long-term growth, while new plants are set to deliver high profitability.
Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group price target lowered to $19 from $24 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Stevanato Group (STVN) to $19 from $24 and keeps an Equal Weight rating on the shares. The firm updated its model following
Stevanato Group price target lowered to $32 from $37 at KeyBanc
KeyBanc lowered the firm’s price target on Stevanato Group (STVN) to $32 from $37 and keeps an Overweight rating on the shares. The firm notes the company’s Q4 print was
Stevanato Group price target lowered to $26 from $32 at Citi
Citi lowered the firm’s price target on Stevanato Group (STVN) to $26 from $32 and keeps a Buy rating on the shares.
Stevanato Group price target lowered to $28 from $30 at BofA
BofA lowered the firm’s price target on Stevanato Group (STVN) to $28 from $30 and keeps a Buy rating on the shares. The firm notes Q4 results were ahead of
Stevanato Group Earnings Call Transcript: Q4 2025
Fiscal 2025 saw strong revenue and margin growth, led by high-value solutions and robust GLP-1 demand. 2026 guidance anticipates continued BDS growth, margin expansion, and high-value solutions reaching up to 48% of revenue, despite currency and engineering headwinds.
Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group price target lowered to $17.50 from $23 at Jefferies
Jefferies lowered the firm’s price target on Stevanato Group (STVN) to $17.50 from $23 and keeps a Hold rating on the shares. Injectable packaging Contract Manufacturing Organizations face headwinds f...
Stevanato Group assumed with an Equal Weight at Morgan Stanley
Morgan Stanley assumed coverage of Stevanato Group (STVN) with an Equal Weight rating and a price target of $24, down from $26. Life Science Tools and Diagnostics end market bright
Stevanato Group Transcript: Jefferies London Healthcare Conference 2025
A leading provider of injection-related pharmaceuticals is expanding global capacity and focusing on high-value solutions for biologics and GLP-1 drugs. Revenue and EBITDA have more than doubled, with robust demand, long-term contracts, and heavy investment in R&D and integrated systems supporting growth. Several hundred molecules are being filed with clients.
Stevanato Group Transcript: Wolfe Research Healthcare Conference 2025
Major CapEx investments and a shift to high-value products are driving growth, especially in biologics and GLP-1s. Policy clarity and reshoring support future U.S. expansion, while engineering segment efficiency is improving despite order timing delays.
Stevanato Group price target raised to $26 from $24 at Morgan Stanley
Morgan Stanley analyst Tejas Savant raised the firm’s price target on Stevanato Group (STVN) to $26 from $24 and keeps an Equal Weight rating on the shares. Published first on
Stevanato Group Earnings Call Transcript: Q3 2025
Q3 revenue grew 9% year-over-year, led by high-value solutions and strong BDS segment growth. Margins expanded, guidance for 2025 was reiterated, and capacity investments continue to support robust demand in biologics and ready-to-use products.
Stevanato Group reports Q3 adjusted EPS EUR0.14 vs. EUR0.12 last year
Reports Q3 revenue EUR303.2M vs. EUR277.9M last year. CEO Franco Stevanato stated, “We delivered a solid Q3 with 9% revenue growth and a record 47% increase in high-value solutions, driven
Stevanato Group sees 2025 adjusted EPS EUR0.50-EUR0.54
Sees 2025 revenue EUR 1.16B-EUR1.19B.
Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group to Participate in Upcoming Investor Conferences
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group to Report Third Quarter 2025 Financial Results on November 6, 2025
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...